Form 4: Precigen CEO Helen Sabzevari Receives Equity Grant
Statement of Changes in Beneficial Ownership
Precigen CEO Helen Sabzevari was granted 1,366,000 stock options and 410,000 restricted stock units on April 20, 2026.
Summary
- Helen Sabzevari, President and CEO of Precigen, Inc., received a new equity compensation package.
- The grant includes 1,366,000 stock options with an exercise price of $4.11.
- The grant includes 410,000 restricted stock units (RSUs), each representing a right to one share of common stock.
- Both the options and RSUs follow a multi-year vesting schedule beginning in May 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, which is a standard corporate governance event.
Positives
- Equity grants align executive interests with long-term shareholder value creation.
- Vesting schedules are structured over several years, encouraging executive retention.
Negatives
- The issuance of 1,776,000 total equity instruments results in potential future dilution for existing shareholders.
Risks
- Future dilution of common stock upon the exercise of options and vesting of RSUs.
- Market price volatility may impact the ultimate value of the equity compensation.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on executive compensation structure.
Industry Context
StockSavvy.ai notes that equity-based compensation is standard practice in the biotechnology sector to incentivize leadership during long-term drug development cycles.
Comparison to Industry Standards
- The use of multi-year vesting schedules (25% initial cliff followed by installments) is consistent with standard corporate governance practices for executive compensation in the biotech industry.
- The grant size is typical for a CEO of a mid-cap or small-cap biotechnology firm.
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise or vesting of these equity instruments.
Next Steps
- Vesting of 25% of options and RSUs on May 23, 2027.
Key Dates
| Date | Description |
|---|---|
| 04/20/2026 | Date of the equity grant transaction. |
| 04/22/2026 | Date of filing. |
| 05/23/2027 | Initial vesting date for both options and RSUs. |
| 04/20/2036 | Expiration date for the stock options. |
Keywords
Precigen, PGEN, Form 4, Executive Compensation, Stock Options, Restricted Stock Units, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.